Search

Researchers from MSK presented findings on graft-versus-host disease and other topics at the annual meeting of bone marrow transplant and cellular therapy experts.

… Monday, February 26, 2024 Doctors and scientists from Memorial Sloan Kettering Cancer Center (MSK) presented advances in transplantation and cellular therapies at a joint meeting hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and

… Monday, September 16, 2024 Selwyn M. Vickers, MD, FACS , the President and CEO of Memorial Sloan Cancer Center, is a renowned pancreatic cancer surgeon, health equity researcher, and hospital leader. But the title he is proudest of is ‘Dad.’  Dr. Vickers and his wife, Janice, have raised four grown children

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

… Friday, February 8, 2019 Summary People newly diagnosed with peripheral T cell lymphoma have traditionally been treated with chemotherapy. A recent study showed that adding a drug called brentuximab vedotin to chemotherapy could stop the disease from progressing and improve survival. Peripheral T cell

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

… Thursday, January 27, 2022 Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows. The new class of AAAS Fellows includes 564 scientists, engineers

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

… Thursday, April 9, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

… Thursday, June 11, 2020 The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.  (1) The best objective response rate (ORR) was 30 percent (95%

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Thursday, July 28, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Ya-Ting Wang and Inaki Etxberria Ya-Ting “Emma” Wang and Inaki Etxberria Receive Prestigious Early Career Researcher Awards Ya-Ting “Emma” Wang , postdoctoral fellow, was named the 2022

… Monday, December 27, 2021 Building on their long-term shared commitment to international collaboration on cancer research and care – Memorial Sloan Kettering Cancer Center (MSK) and the Chinese Thoracic Oncology Group (CTONG), an alliance of more than 30 premier academic cancer centers in China – joined

Learn how testicular cancer is often misunderstood and why it is highly treatable.

… Thursday, June 29, 2023 Highlights Testicular cancer Testicular cancer is a rare but very curable disease. Testicular cancer strikes younger men (people whose sex assigned at birth was male). An injury to your testicles (getting “hit in the balls”) does not cause testicular cancer.   Many people with

Read about a new treatment for people with some ER+, HER2- advanced breast cancers.

… Friday, December 12, 2025 Updated results from a clinical trial show that a new treatment continues to be effective at stopping advanced breast cancer from progressing in some people with tumors that have grown resistant to standard therapy. The new data also suggests that overall survival can be improved